A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma

OBJECTIVE: Nivolumab plus other drugs have provided significant benefits in patients with metastatic renal cell carcinoma (mRCC), but most of the available comparisons were conducted with sunitinib, and differences in efficacy with targeted drugs were marginally reported. Thus, this study used a net...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Hongchen, Mu, Zhongyi, Wang, Kai, Hu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979733/
https://www.ncbi.nlm.nih.gov/pubmed/35386213
http://dx.doi.org/10.1155/2022/5805289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979733/
https://www.ncbi.nlm.nih.gov/pubmed/35386213
http://dx.doi.org/10.1155/2022/5805289

Ejemplares similares